Clinical Trial Imaging Market: By Product & Services (Software and Services), By Modality (Computed Tomography, Magnetic Resonance Imaging, Ultrasound, Positron Emission Tomography, X-Ray, Echocardiography and Other Modalities), By End-User (Pharmaceutical Companies, Biotechnology Companies, Medical Device Manufacturers, Contract Research Organizations, Academic and Government Research Institutes and Other End-Users) and By Geography

Clinical Trial Imaging Market size was valued at USD 1,286.2 million in 2022, is growing at a CAGR of 7.9% from 2023 to 2029. By product and services, the global clinical trial imaging market has been segmented into Software and Services. The Services segment is likely to be the largest and fastest-growing segment in terms of products and services in 2022 and is expected to maintain the trend in the forecasted years sue to increasing spending in R & D sector and rapid growth in the pharmaceutical sector. Based on modality, the global clinical trial imaging market is segmented into Computed Tomography, Magnetic Resonance Imaging, Ultrasound, Positron Emission Tomography, X-Ray, Echocardiography, and Other Modalities. Among these, the Computed Tomography segment is expected to have the fastest-growing market during the forecast period 2023-2029. It is attributed to increasing number of CROs, increase in research investments, and growth in pharma sector. Based on end user, the global clinical trial imaging market is segmented into Pharmaceutical Companies, Biotechnology Companies, Medical Device Manufacturers, Contract Research Organizations, Academic and Government Research Institutes and Other End-Users. The Pharmaceutical Companies segment accounts for the largest share in 2022 and is expected to maintain the trend in the forecasted years. However, high implementation cost of imaging systems and high capital required to run clinical trials are hindering the market growth. The market is predicted to rise due to the growing biotechnology and pharmaceutical sectors, as well as rising research and development investments for generating new pharmaceuticals to treat ailments.  

Clinical Trial Imaging Market Key Developments:

• In May 2021, IXICO Plc. (UK) signed a contract with biopharmaceutical client IXICO to provide neuroimaging services for a Phase III clinical trial under this contract.